Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company's ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
SymbolNASDAQ:CASC
CUSIP68232410
Phone+1-206-8012100
Debt
Debt-to-Equity RatioN/A
Current Ratio8.07
Quick Ratio8.07
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.16 per share
Price / Book4.64
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-56,930,000.00
Net MarginsN/A
Return on Equity-43.53%
Return on Assets-40.90%
Miscellaneous
Employees57
Outstanding Shares50,620,000
Market Cap$506.61 million
Cascadian Therapeutics (NASDAQ:CASC) Frequently Asked Questions
What is Cascadian Therapeutics' stock symbol?
Cascadian Therapeutics trades on the NASDAQ under the ticker symbol "CASC."
How were Cascadian Therapeutics' earnings last quarter?
Cascadian Therapeutics Inc (NASDAQ:CASC) released its quarterly earnings data on Wednesday, November, 8th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.29) by $0.01. During the same quarter in the prior year, the company earned ($0.09) EPS. View Cascadian Therapeutics' Earnings History.
What price target have analysts set for CASC?
2 analysts have issued twelve-month price objectives for Cascadian Therapeutics' stock. Their forecasts range from $10.00 to $10.00. On average, they expect Cascadian Therapeutics' share price to reach $10.00 in the next twelve months. This suggests that the stock has a possible downside of 0.2%. View Analyst Price Targets for Cascadian Therapeutics.
What is the consensus analysts' recommendation for Cascadian Therapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cascadian Therapeutics in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cascadian Therapeutics.
Who are Cascadian Therapeutics' key executives?
Cascadian Therapeutics' management team includes the folowing people:
- Christopher S. Henney Ph.D., Chairman of the Board (Age 76)
- Scott D. Myers, President, Chief Executive Officer, Director (Age 51)
- Julia Marie Eastland, Chief Financial Officer, Vice President - Corporate Development, Secretary (Age 51)
- Gary W. Christianson, Chief Operating Officer (Age 61)
- Scott Peterson Ph.D., Chief Scientific Officer (Age 54)
- Robert W. Azelby, Director (Age 49)
- Gwendolyn A. Fyfe M.D., Independent Director (Age 65)
- Steven P. James, Independent Director (Age 58)
- Ted W. Love M.D., Independent Director (Age 58)
- Daniel Keith Spiegelman, Independent Director (Age 58)
Has Cascadian Therapeutics been receiving favorable news coverage?
Headlines about CASC stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cascadian Therapeutics earned a coverage optimism score of 0.18 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 46.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for Cascadian Therapeutics.
How do I buy shares of Cascadian Therapeutics?
Shares of CASC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cascadian Therapeutics' stock price today?
One share of CASC stock can currently be purchased for approximately $10.02.
How big of a company is Cascadian Therapeutics?
Cascadian Therapeutics has a market capitalization of $506.61 million. Cascadian Therapeutics employs 57 workers across the globe.
How can I contact Cascadian Therapeutics?
Cascadian Therapeutics' mailing address is 3101 Western Ave Ste 600, SEATTLE, WA 98121-3047, United States. The biopharmaceutical company can be reached via phone at +1-206-8012100 or via email at [email protected]
MarketBeat Community Rating for Cascadian Therapeutics (NASDAQ CASC)
MarketBeat's community ratings are surveys of what our community members think about Cascadian Therapeutics and other stocks. Vote "Outperform" if you believe CASC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CASC will underperform the S&P 500 over the long term. You may vote once every thirty days.
